Boehringer Ingelheim and Roche partner on inflammatory bowel disease research

Boehringer Ingelheim has announced a new partnership with Roche on the development of new treatments for inflammatory bowel diseases.

The companies will work together to discover and develop new orally available novel locked nucleic acid oligonucleotides for the treatment of various conditions, leveraging their complementary expertise and innovative technology.

Under the terms of the agreement, the partners have committed to sharing clinical development costs and responsibility for the commercialisation of potential products.

This collaboration aligns with Boehringer Ingelheim's strategy of creating new therapies for diseases of the immune system, supported by partnerships, innovation and a commitment to Immunology research and development.

Jay Fine, global head of immunology and respiratory disease research at Boehringer Ingelheim, said: "The opportunity to work closely with the experts at Roche to discover and develop oral, gut-targeted LNAs for the treatment of unmet medical needs in patients suffering from inflammatory bowel diseases is extremely motivating."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.